Attachment 11 - Toxic Materials Survey.pdf

Final Design Submittal

Appendix E Environmental Survey

ACM & Lead Testing Report Mold Testing Report PCB Testing Report

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110 Malcom Randall VA Medical Center, Gainesville, Florida

Page App E - 2

This Page is Blank.

LIMITED RENOVATION ASBESTOS AND LEAD-

CONTAINING PAINT SURVEY REPORT

Renovate Common Area Restrooms

Project 573-20-604 Malcom Randall VA Medical Center

1601 SW Archer Road Gainesville, Florida 32608-1197

GLE Project No.: 22950-00685

Prepared for:

Mr. Thomas Steele Toland Mizell Molnar, LLC

590 Means Street NW, Suite 200 Atlanta, Georgia 30318

May 2022

Prepared by:

App E - 3

May 9, 2022

Mr. Thomas Steele Sent via e-mail: tsteele@toland-mizell-molnar.com Toland Mizell Molnar, LLC 590 Means Street NW, Suite 200 Atlanta, Georgia 30318

RE: Limited Renovation Asbestos and Lead-Containing Paint Survey Report

Renovate Common Area Restrooms Project 573-20-604 Malcom Randall VA Medical Center 1601 SW Archer Road Gainesville, Florida 32608-1197

GLE Project No.: 22950-00685

Dear Mr. Steele:

GLE Associates, Inc. (GLE) performed a limited renovation survey for asbestos-containing materials (ACM) and lead containing paint (LCP) between March 7 and March 24, 2022, at the Malcom Randal VA Medical Center, located in Gainesville, Florida. The survey was performed by Mr. Michael D. Harrell and Mr. Mark Fohn with GLE. This report outlines the sampling and testing procedures and presents the results along with our conclusions and recommendations.

GLE appreciates the opportunity to serve as your consultant on this project. If you should have any questions, or if we can be of further service, please do not hesitate to call.

Sincerely, GLE Associates, Inc.

Michael D. Harrell Robert B. Greene, PE, PG, CIH, LEED AP Senior Project Manager President

Florida LAC# EA 0000009

MDH/RBG/jl

\\gvlsvr\sys\Work\Asbestos\'22\22950 - VA\00685 - TMM MRMC Bathroom Renovations ACM, Pb, PCBs, Mold\Report\Asbestos and Lead\ACMPbSurveyReport.docx

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110 Malcom Randall VA Medical Center, Gainesville, Florida

App E - 4 mailto:tsteele@toland-mizell-molnar.com

TABLE OF CONTENTS

1.0 INTRODUCTION 1

1.1 Introduction 1

1.2 Facility Description 1

2.0 ASBESTOS 2

2.1 Asbestos Survey Procedures 2

2.2 Identified Suspect Asbestos-Containing Materials 3

Table 2.2-1 — Summary of Homogeneous Sampling Areas

3.0 LEAD-CONTAINING PAINT 11

3.1 Lead-Containing Paint Survey Procedures 11

3.2 Identified Suspect Lead-Containing Paint 11

Table 3.2-1 — Summary of Suspect Lead-Containing Paint Analytical Results

4.0 CONCLUSIONS AND RECOMMENDATIONS 16

4.1 Asbestos - General 16

4.1.1 Asbestos - Specific 16

4.2 Lead-Containing Paint 18

5.0 LIMITATIONS AND CONDITIONS 19

APPENDICES

Appendix A – Analytical Results and Chains of Custody Appendix B – Personnel and Laboratory Certifications Appendix C – Sample Location Plans Appendix D – Photographs

App E - 5

1.0 INTRODUCTION

1.1 INTRODUCTION

The purpose of this limited renovation survey was to identify accessible asbestos-containing materials (ACMs) and lead-containing paint (LCP) and their general locations within the Malcom Randall VA Medical Center, located at 1601 SW Archer Road in Gainesville, Florida.

The scope of the survey was limited to client-identified common area restrooms, as depicted in the Toland Mizell Molnar, LL provided list and drawings, dated February 7, 2022. The asbestos survey was conducted pursuant to National Emission Standards for Hazardous Air Pollutants (NESHAP, 40 CFR 61) requirements, associated with the scheduled renovations plans. The survey was performed on March 7-9, 11, and 22-24, 2022, by Mr. Michael D. Harrell, an Environmental Protection Agency/Asbestos Hazard Emergency Response Act (EPA/AHERA) accredited inspector and EPA Lead Risk Assessor, and Mr. Mark Fohn, Environmental Protection Agency/Asbestos Hazard Emergency Response Act (EPA/AHERA) accredited inspector. The scope of this survey did not include demolition of any building components, evaluation of architectural plans, or removal cost estimating.

1.2 FACILITY DESCRIPTION

A summary of the facility investigated is outlined in the table below.

Building 1

Facility Type: Medical Construction Date: 1967 Number of Floors: Two in Scope

Exterior Floor Support: Concrete Slab on Grade Wall Support: Concrete Block (CMU), Precast Concrete Panels

Exterior Finish: Not In Scope Roof System Type: Not In Scope

Interior Wall Substrate: Drywall and Joint Compound, Plaster, Drywall Wall Finishes: Paint, Ceramic Tile, Cove Base Floor Finishes: Vinyl Floor Tile, Ceramic Tile Ceiling System: Drywall and Joint Compound, Suspended Ceiling System Ceiling Finishes: Paint, Suspended Ceiling Tiles

App E - 6

Building 12 Facility Type: Medical

Construction Date: Unknown Number of Floors: One in Scope

Exterior Floor Support: Concrete Slab on Grade Wall Support: Concrete Block (CMU), Precast Concrete Panels

Exterior Finish: Not In Scope Roof System Type: Not In Scope

Interior Wall Substrate: Drywall and Joint Compound, Plaster Wall Finishes: Paint, Ceramic Tile, Cove Base Floor Finishes: Vinyl Floor Tile, Ceramic Tile Ceiling System: Suspended Ceiling System, Plaster Ceiling Finishes: Suspended Ceiling Tiles, Paint

2.0 ASBESTOS

2.1 ASBESTOS SURVEY PROCEDURES

The survey was performed by visually observing accessible areas within the scope of work.

EPA/AHERA accredited inspectors performed the visual observations (refer to Appendix B for personnel qualifications).

After the overall visual survey was completed, representative sampling areas were determined.

The surveyors delineated homogeneous areas of suspect materials and samples of each material were obtained, in general accordance with regulations as established by the Occupational Safety and Health Administration (OSHA) and NESHAP. The field surveyors determined sample locations based on previous experience. Both friable and non-friable materials were sampled. A friable material is one that can be crushed when dry by normal hand pressure. This survey did not include the demolition of building components to access suspect material.

After completion of the fieldwork, the samples were delivered to GLE’s National Voluntary Laboratory Accreditation Program (NVLAP) accredited laboratory for analysis. The samples were analyzed by Polarized Light Microscopy (PLM) coupled with dispersion staining, in general accordance with EPA-600/R-93/116. Utilizing this procedure, the various asbestos minerals (chrysotile, amosite, crocidolite, actinolite, tremolite, and anthophyllite) can be determined. The percentages of asbestos minerals in the samples were visually determined by the microscopist. Please note that the EPA designates all materials containing greater than one percent asbestos as an “asbestos-containing material” (ACM).

Regulated Asbestos-Containing Material (RACM) is defined as (a) Friable asbestos materials,

(b) Category I non-friable ACM that has become friable, (c) Category I non-friable ACM that will be or has been subjected to sanding, grinding, cutting, or abrading, or (d) Category II non-

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 7 friable ACM that has a high probability of becoming or has become crumbled, pulverized, or reduced to powder by the forces expected to act on the material in the course of demolition or renovation operations regulated by this subpart.

Category I and Category II non-friable ACM, as defined by the EPA:

▪ Category I non-friable ACM means asbestos-containing packings, gaskets, resilient floor covering, asphalt roofing products, and pliable sealants and mastics that are in good condition and not friable, containing more than one percent asbestos, as determined using the method specified in Appendix E, Subpart E, 40 CFR Part 763, Section 1, PLM.

▪ Category II non-friable ACM means any material, excluding Category I non-friable ACM, containing more than 1 percent asbestos as determined using the methods specified in Appendix E, Subpart E, 40 CFR Part 763 Section 1, PLM that, when dry, cannot be crumbled, pulverized, or reduced to powder by hand pressure.

2.2 IDENTIFIED SUSPECT ASBESTOS-CONTAINING MATERIALS

A total of three hundred fifty-five samples of suspect building materials were collected from the facility during the survey, representing one hundred seventeen different identified homogeneous areas. The results of the laboratory analyses are included in Appendix A, and the approximate extent to which ACM was observed to be present is indicated on the Asbestos Sample Location Plans in Appendix C. Photographs of the various materials sampled are included in Appendix D.

Due to accessibility issues, access to plenum spaces was limited throughout.

A summary of the homogenous sampling areas of suspect ACM determined to be present is outlined in the following table.

App E - 8

T

A B

L E

.2

-1 : S

U M

M A

R Y

O F

H O

M O

G E

N E

O U

S

SA

M

PL

IN

G

A R

E A

S R

E N

O V

A T

E C

O M

M O

N A

R E

A R

E

ST

R O

O M

S

PR

O

JE

C T

-2 0-

M A

L C

O M

R A

N D

A L

L V

A M

E D

IC

A

L C

E N

T E

R

S W

A R

C H

E R

R O

A D

G

A

IN

E

SV

IL

L

E , F

L O

R

ID

H

H

O M

O G

E N

E O

U S

M A

T E

R

IA

L

D

SC

R

IP

T

IO

N

O M

O G

E N

E O

U S

M A

T E

R

C A

T

FR

B

IL

IT

Y

(F

/N F)

SB

E

ST

S*

F

SA

M

PL

E

S C

O L

L E

C T

PP

R

O X

IM

A

T E

Q U

A N

T

C

M

T E

G O

T-

2' x

' W hi te

F is su re d C ei lin g Ti le

B

4- 1, B

2- 1, C

1- 1, a nd

3A

-1

F

IS

' W hi te

R ec es se d Fi ss ur ed C ei lin g

5- 1, D

3- 1, B

1- 1, A

9- 1, 1-

1, D

1-

1, D

9-

1, 0-

F

' W hi te

F is su re d C ei lin g

0-

(A

7-on d ra w in g)

A

8-

1, B

5-

1, A

4-

1, A

5-

2-

F

' W hi te

P in ho le

C ei lin g

4-

1, B

3-

1, B

4-

1, B

1-

0- 1, D

2- 1, D

0- 1, D

4-

F

' W hi te

F is su re d w ith P in ho le s

C ei lin g

7-

F

' W hi te

F is su re d w ith P in ho le s

C ei lin g

' W hi te

P in ho le

C ei lin g

4A

-1 a nd C

3-

F

' W hi te

R ec es se d Fi ss ur ed C ei lin g

E1

-1 , E

6-

1, E

B

-1 , E

B

-1

F1

-1 , F

6-

1, F

B

-1 , F

B -0

3-

G

3-

1, a nd G

4-

F

' W hi te

F is su re d C ei lin g

EB

-1 a nd E

B0 4-

F

' W hi te

F is su re d C ei lin g

6-

, 1

-1

2, -1

2, 2, , 1

-1

2, a nd

-1

F

W

-0

D ry w al l N or th

W al l, B

4-

N

F

-0

D ry w al l w ith

Jo in t C om po un d W al ls

, A

0A -1

, W al ls a nd C ei lin g A

1-

App E - 9

B L

E

.2 -1

: S U

M M

A R

Y O

F H

O M

O G

E N

E O

U S

SA

M

PL

IN

G A

R E

A S

R E

N O

V A

T E

C O

M M

O N

A R

E A

R E

ST

R

O O

M S

PR

O

JE

C

T

-2

0-

M

A L

C O

M R

A N

D A

L L

V A

M E

D

IC

A L

C E

N T

S

W A

R C

H E

R R

O A

D

G A

IN

E

SV

IL

L E

, F L

O R

H

O M

O G

E N

E O

U S

M A

T E

R

SC

R

IP

T

M

O G

E N

E O

U S

M A

T E

R

C A

T

B

IL

SB

E

ST

F

SA

M

PL

E

S C

O L

L E

C T

R

O X

IM

A

T E

Q U

A N

T

T E

G O

-0

D ry w al l w ith

Jo in t C om po un d A

7-

1, A

8-

1, A

8A

-1 , A

5- 1, B

5A -1

, a nd

B

3-

N F

-0

D ry w al l w ith

Jo in t C om po un d B

3-an d B2

-0

D ry w al l w ith

J oi nt C om po un d

B

1-

W es t W al ls a nd B

2-

E as t C ei lin g N

F

D ry w al l-N D

Jo in t C om po un d-

5%

C om po si te

1%

SF

-0

D ry w al l w ith

Jo in t C om po un d D

0-

N

F

-0

D ry w al l w ith Jo in t C om po un d

D

9-an d

D

0-

N F

-0

D ry w al l C

2-

N

F

-0

D ry w al l w ith Jo in t C om po un d

E1

-1

D ry w al l w ith

Jo in t C om po un d E1

-1

D ry w al l w ith Jo in t C om po un d

E1

-1 W al ls a nd

C ei lin g

N F

-1

D ry w al l w ith

Jo in t C om po un d

EB

-1 a nd

E B4

6-

N F

-1

D ry w al l w ith

Jo in t C om po un d

EB

-1 a nd

E B0

4-

N F

-1

D ry w al l w ith

Jo in t C om po un d F1

-1 a nd

F

5-

N F

-1

D ry w al l w ith

Jo in t C om po un d

FB

-1 a nd

F B0

3-

N F

-1

D ry w al l w ith

Jo in t C om po un d G

3-an d G

4-

N

F

-1

D ry w al l w ith

Jo in t C om po un d

6-

, 1

-1 2, -1 2, , 1

-1 2, a nd

-1

N F

-1

D ry w al l w ith

Jo in t C om po un d W al l b et w ee n

C

3-an d

C

FT

-0

" x

2" W hi te

F lo or T ile w ith Y el lo w lu e D

4-

N

F

App E - 10

B L

E

.2 -1

: S U

M M

A R

Y O

F H

O M

O G

E N

E O

U S

SA

M

PL

IN

G A

R E

A S

R E

N O

V A

T E

C O

M M

O N

A R

E A

R E

ST

R

O O

M S

PR

O

JE

C

T

-2

0-

M

A L

C O

M R

A N

D A

L L

V A

M E

D

IC

A L

C E

N T

S

W A

R C

H E

R R

O A

D

G A

IN

E

SV

IL

L E

, F L

O R

H

O M

O G

E N

E O

U S

M A

T E

R

SC

R

IP

T

M

O G

E N

E O

U S

M A

T E

R

C A

T

B

IL

SB

E

ST

F

SA

M

PL

E

S C

O L

L E

C T

R

O X

IM

A

T E

Q U

A N

T

T E

G O

" x

2" B lu e

Fl oo r T ile w ith

Y el w e

D

4-

N F x

B ei ge F lo or

T ile w ith

B la ck as tic a nd

-1

N

F T ile

- N

D

M as tic

- 5

T I

M -0

W hi te

C er am ic

T ile

G ro ut

4-

N F

G ra y

C er am ic

T ile

G

5-

N F

Sp ec kl ed E po xy

F lo or in g N ew ly

A pp lie d ov er

C er am ic ile

Th ug ho

Ta n C er am ic T ile G

0-

N

F

W hi te C au lk

0-

D oo r

N F

G ra y

C er am ic

T ile

G

1-

N F

Ta n C er am ic T ile G

3-

N

F

Ta n

C er am ic

T ile

G

8-an d

B0

-1 S ui te

W al ls

W hi te

C

8-an d

B0

-1 S ui te

D oo rs

G ra y

C er am ic

T ile

G

8-an d

B0

-1 S ui te

F lo or s

N F

G ra y

C er am ic

T ile

G

7-

N F

W hi te

C er am ic

T ile

G

6-

N F

W hi te

C er am ic

T ile

G

4-an d

B2

W hi te

C er am ic

T ile

G

4-an d

B2

G ra y

C er am ic

T ile

G

1-an d

B2

G ra y

C er am ic

T ile

G

0-

N F

Ta n C er am ic T ile G

9-

N

F

W hi te C er am ic T ile G

1-

N

F

-2

O ra ng e

C er am ic

T ile

G

1-

N F

App E - 11

B L

E

.2 -1

: S U

M M

A R

Y O

F H

O M

O G

E N

E O

U S

SA

M

PL

IN

G A

R E

A S

R E

N O

V A

T E

C O

M M

O N

A R

E A

R E

ST

R

O O

M S

PR

O

JE

C

T

-2

0-

M

A L

C O

M R

A N

D A

L L

V A

M E

D

IC

A L

C E

N T

S

W A

R C

H E

R R

O A

D

G A

IN

E

SV

IL

L E

, F L

O R

H

O M

O G

E N

E O

U S

M A

T E

R

SC

R

IP

T

M

O G

E N

E O

U S

M A

T E

R

C A

T

B

IL

SB

E

ST

F

SA

M

PL

E

S C

O L

L E

C T

R

O X

IM

A

T E

Q U

A N

T

T E

G O

W hi te

D uc t T ap e D

1-

N

F

B la ck C er am ic T ile G

2-

N

F

W hi te C er am ic T ile G

0-

N

F

Ta n

C er am ic

T ile

G

1-

N F

W hi te

C er am ic

T ile

G

4-

N F

G ra y

C er am ic

T ile

G

4A -1

W al ls a nd F or

<1

C re am C er am ic T ile G

9-an d D

0-

N

F

W hi te C t D ec k in

P le nu m

, D

9-

N F

L F

C A

T I

M -2

W hi te

C er am ic

T ile

G

4-

N F

-3

Ta n C er am ic T ile G

5-

N

F

W hi te C er am ic T ile G

2-

N

F

W hi te C er am ic T ile G

Ta n

C er am ic

T ile

G

G ra y

C er am ic

T ile

G

W hi te

C

-1 D oo r

N F

W hi te

C

-1 D oo r

N F

G ra y

C er am ic

T ile

G

W hi te

C

-1 a nd E

B4 6-

D

C re am C er am ic T ile G

-1 a nd

E B0

4-

N F

-4

W hi te

C

-1 a nd E

B0 4-

D

W hi te C

F1

-1 a nd

F

5-

D

W hi te

C er am ic

T ile

G

-1 a nd F

5-

N

F

W hi te C

FB

-1 a nd

F B0

3-

D

App E - 12

B L

E

.2 -1

: S U

M M

A R

Y O

F H

O M

O G

E N

E O

U S

SA

M

PL

IN

G A

R E

A S

R E

N O

V A

T E

C O

M M

O N

A R

E A

R E

ST

R

O O

M S

PR

O

JE

C

T

-2

0-

M

A L

C O

M R

A N

D A

L L

V A

M E

D

IC

A L

C E

N T

S

W A

R C

H E

R R

O A

D

G A

IN

E

SV

IL

L E

, F L

O R

H

O M

O G

E N

E O

U S

M A

T E

R

SC

R

IP

T

M

O G

E N

E O

U S

M A

T E

R

C A

T

B

IL

SB

E

ST

F

SA

M

PL

E

S C

O L

L E

C T

R

O X

IM

A

T E

Q U

A N

T

T E

G O

W hi te

C er am ic

T ile

G

-1 a nd F

B0 3-

N

F

W hi te C er am ic T ile G

3-an d G

4-

N

F

W hi te C er am ic T ile G

W hi te

C

, 1

-1

2, -1

2, , 1

-1

2, a nd

-1

D

W hi te

C er am ic

T ile

G

, 1

-1

2, -1

2, -1

2, G ra y

C er am ic

T ile

G

3-

N F

-5

W hi te

C er am ic

T ile

G l B et w ee n C

3-an d C

S-re am

D uc t M

Fo il

D uc ts in

B

5-

N F

S

F C

A T

I M

A

Li gh t G ra y D uc t M et al

D uc ts in

B

4-an d

B

5-

N F an M

Pn eu m at ic T ub e

In su la tio n M in oo m s D

3-

1, D

4-

1, A

0-

6- 1, B

5- 1, B

1- 1, A

0-

1, D

4-

1, A

4-

1, 5-

N F

L F

C A

T I

M A ra y

M al D uc t i n A

0-

N

F hi te M

W ra pp ed D uc t i n A

1-

N

F y M al

D uc t i n

D

4-

N F te

D uc t M

W ra pp ed

D uc ts in

A

8-an d

B

5-

Su ite s N

F y

M al D uc ts in A

8-an d B

5-

Su ite s

N F ei ge

D uc t M al E xh au st D uc ts in A

6-an d A

7-

N

F

App E - 13

B L

E

.2 -1

: S U

M M

A R

Y O

F H

O M

O G

E N

E O

U S

SA

M

PL

IN

G A

R E

A S

R E

N O

V A

T E

C O

M M

O N

A R

E A

R E

ST

R

O O

M S

PR

O

JE

C

T

-2

0-

M

A L

C O

M R

A N

D A

L L

V A

M E

D

IC

A L

C E

N T

S

W A

R C

H E

R R

O A

D

G A

IN

E

SV

IL

L E

, F L

O R

H

O M

O G

E N

E O

U S

M A

T E

R

SC

R

IP

T

M

O G

E N

E O

U S

M A

T E

R

C A

T

B

IL

SB

E

ST

F

SA

M

PL

E

S C

O L

L E

C T

R

O X

IM

A

T E

Q U

A N

T

T E

G O am

D uc t M

W ra pp ed

D uc t i n

A

6-

N F

S

F C

A T

I M

A ge D uc t M al

D uc ts in

B

3-an d

B

4-

N F ge

M ou nd M et al

D uc t i n

B

2-

N F

Ta n M al

D uc t i n

A

0-

N F

M al

D uc t i n

D

0-

N F te

M

W ra pp ed

D uc t i n

D

4-

N F

S F

C A

T I

M A y

M al D uc t i n C

2-

N

F y M

Sm l M et al

D uc t i n

E1 y

M al D uc t i n E1 te

D uc t M

W ra pp ed

D uc ts in

E B d E

B

S F

C A

T I

M A te

D uc t M

W ra pp ed

D uc ts in

E B d E

B

S F

C A

T I

M A y

M al D uc ts in F

4-an d F1 y M al

D uc ts in

F B

-1 a nd

F B y M al

D uc t i n

G

3-

N F

M al

D uc ts in

-1 2, -1 2, , 1

-1 2, -1 2, -1 2, PL

W hi te o ve r T an

P la st er ug ho ut

B ui ld in g 1, S ec tio ns

A

W hi te o ve r T an

P la st er

2-a nd

-1

O ve r T oi ts

TS

I-te

M as tic o n Fi be rg ss

1-

N

F

App E - 14

B L

E

.2 -1

: S U

M M

A R

Y O

F H

O M

O G

E N

E O

U S

SA

M

PL

IN

G A

R E

A S

R E

N O

V A

T E

C O

M M

O N

A R

E A

R E

ST

R

O O

M S

PR

O

JE

C

T

-2

0-

M

A L

C O

M R

A N

D A

L L

V A

M E

D

IC

A L

C E

N T

S

W A

R C

H E

R R

O A

D

G A

IN

E

SV

IL

L E

, F L

O R

H

O M

O G

E N

E O

U S

M A

T E

R

SC

R

IP

T

M

O G

E N

E O

U S

M A

T E

R

C A

T

B

IL

SB

E

ST

F

SA

M

PL

E

S C

O L

L E

C T

R

O X

IM

A

T E

Q U

A N

T

T E

G O

SI

-0

B la ck E lb ow

M ad ia nt

H ea t P ip in g

E lb ow s i n D

4-

1, A

9-

1, a nd B

2-

N

F

S

F C

A T

I

TS

ck M ad ia nt H ea t P ip in g in

D

4-

9-

1, a nd B

2-

N

F

SI

-0

B la ck E lb ow

M

2” P ip e in D

0-

N

F

T

I

T

SI

-0

W hi te M as tic o ve r E lb ow ud in

L in e E lb ow s i n

EB

-1

M as tic

-1 0% ud

-N

S

F C

A T

I

TS

te M as tic o n

Fi be rg te M as tic o n

Fi be rg

-1 a nd F

B0 3-

N

F ck

M as tic o n Fo am gl as s

8-a nd

-1

N

F

V

-0

6"

G ra y C ov e

B as e w ith W hi te

G lu e D

4-

N

F

-0

4"

B la ck C ov e

B as e w ith T an M

-0

4" B lu e/

G re en C ov e

B as e w ith

App E - 15

3.0 LEAD-CONTAINING PAINT

3.1 LEAD-CONTAINING PAINT SURVEY PROCEDURES

The lead-containing paint survey was performed by visually observing accessible painted component surfaces associated with the scope of work. The protocol used in this lead paint survey is a modified version of the survey methodology established by HUD. The protocol was modified to conform to the specific parameters of this project. An EPA Risk Assessor performed the visual observations.

During the walk through of the facility, each area was observed, and an inventory of painted surfaces was developed. The surveyor then subdivided the areas into homogeneous areas of apparent similar paint history.

Testing of the painted surfaces was performed by collecting representative paint chips. All samples were submitted to EMSL Analytical, Inc., an accredited laboratory recognized under EPA’s National Lead Laboratory Accreditation Program (NLLAP). These samples were analyzed by EPA Method 3050B/7000B and the results are reported in percentage of lead by weight of the paint sample (% Wt). Please note that any detectable concentration of lead in the paint is designated by OSHA as “lead-containing.”

3.2 IDENTIFIED SUSPECT LEAD-CONTAINING PAINT

The identified suspect lead-containing coatings are described in the following table:

App E - 16

B

L E

.2

-1

SU

M

M A

R Y

O F

A N

A L

Y T

IC

A

L R

E

SU

L T

S R

E N

O V

A T

E C

O M

M O

N A

R E

A R

E

ST

R O

O M

S

PR

O

JE

C T

-2 0-

M A

L C

O M

R A

N D

A L

L V

A M

E D

IC

A

L C

E N

T

S W

A R

C H

E R

R O

A D

G

A

IN

E

SV

IL

L

E , F

L O

R

SA

U

IL

D

IN

E R

IO

R

X T

E R

C A

T

M

PO

N E

L

N C

E N

T R

A T

Y

W E

IG

H

T

L-ui ld in g

In te rio r B

5-

Pl as te r W am

0.

B ui ld in g

In te ri

4- 1, B

5- 1, D

3- 1, D

4- 1, D

0- 1, C

1- 1, a nd

C

3-

M et al D oo r

Fr es ig ht B lu e

0.

ld in g

In te rio r B

4-

1, B

5-

1, D

3-

1, D

4-

1, C

1-

1, a nd C

3-

W oo d

D t B lu e

0.

ld in g

In te rio r A

0A

-1 a nd A

1-

D ry w al l W al ls a nd

C ei lin gs te ld in g

In te rio r A

0A

Pl te r W ld in g

In te rio r A

0A

-1 a nd A

1-

M et al

D oo r F ra m t B lu e

0.

ld in g

In te rio r D

3-an d D

4-

Pl as te r W ld in g

In te rio r

A

8-

Su ite ry w al l W ld in g

In te rio r A

8-te r W ld in g

In te rio r A

8-w al l W t B lu e

0.

ld in g

In te rio r A

8-al D oo r F ra

L -1

B ui ld in g

In te

7-

In te ri or

M et al D oo r

Fr am e B ge ld in g

In te rio r A

7-

Ex te rio r M et al D oo r F ra m e A qu a

0.

ld in g

In te rio r

A

6-an d

A

7-

W oo d D ld in g

In te rio r A

6-an d A

7-

Pl as te r W

B ui ld in g

In te

6-

M et al D oo r

Fr am e an d Pa rt iti on s

B ro w n

0.

ld in g

In te rio r A

6-

W oo d

D oo r B ro w n

0.

B ui ld in g

In te

4-

In te ri or

M et al D oo r

Fr am e B lu e/

G ra y 0.

ld in g

In te rio r B

4-

In te rio r W oo d D oo r

B lu e/ G ra y

0.

B ui ld in g

In te

4-

M et al

S ta ll Pa rt iti on s

B lu e/ G ra y

B ui ld in g

In te

3- 1, B

4- 1, A

9- 1, A

0- 1, D

2- 1, D

0- 1, a nd

D

1-

D oo r Fr ea l

App E - 17

B L

E

.2 -1

SU

M M

A R

Y O

F A

N A

L Y

T

IC

A L

R E

SU

L

T S

R E

N O

V A

T E

C O

M M

O N

A R

E A

R E

ST

R

O O

M S

PR

O

JE

C

T

-2

0-

M

A L

C O

M R

A N

D A

L L

V A

M E

D

IC

A L

C E

N T

S

W A

R C

H E

R R

O A

D

G A

IN

E

SV

IL

L E

, F L

O R

U

IL

D

E R

IO

R

T

E R

C A

T

M

PO

N E

L

N C

E N

T R

A T

Y

W E

IG

H

T ld in g

In te rio r B

3-an d B2 d

D ld in g

In te rio r

B

1-an d

B2 al D oo r F ra

Te ld in g

In te rio r B

1-an d B2 d

D y

0.

ld in g

In te rio r

B

1-an d

B2 te r W ld in g

In te rio r B

1-an d B2 w al l W ld in g

In te rio r B

2-

C er am ic T ile W al ls

, F lo or an d

B en ch y

0.

ld in g

In te rio r A

9-an d A

0-

W oo d

D y

0.

ld in g

In te rio r A

9-

Pl as te r W ld in g

In te rio r

A

1-

M et al D oo r F ra m e Ta n

0.

ld in g

In te rio r A

1-an d A

2-

W oo d

D ld in g

In te rio r

A

1-an d

A

2-

Pl as te r W

B ui ld in g

In te

0-an d

D

1-

W oo d D y

0.

ld in g

In te rio r

D

0-

Pl as te r S ou th

W al l C ld in g

In te rio r D

0-

D ry w al l W ld in g

In te rio r D

1-

In te rio r M et al D oo r F ra m e Li gh t T ld in g

In te rio r

D

1-

Pl as te r S ou th

W al l Li gh ld in g

In te rio r

D

1-

D ry w al l W ld in g

In te rio r D

4-

In te rio r M et al D oo r F ra m e ld in g

In te rio r

D

4-

Ex te rio r M et al

D oo r F ra m e

C ld in g

In te rio r

D

4-

In te rio r W oo d

D oo r Li gh t G ra y

0.

ld in g

In te rio r D

4-

Ex te rio r W oo d D oo r

C ld in g

In te rio r

D

4-

Pl as te r W t G ra y

0.

-5

B ui ld in g

In te

4A te r

W ld in g

In te rio r

D

9- 1, D

0- 1, A

4- 1, a nd

A

5-

M et al D oo r F ra

App E - 18

B L

E

.2 -1

SU

M M

A R

Y O

F A

N A

L Y

T

IC

A L

R E

SU

L

T S

R E

N O

V A

T E

C O

M M

O N

A R

E A

R E

ST

R

O O

M S

PR

O

JE

C

T

-2

0-

M

A L

C O

M R

A N

D A

L L

V A

M E

D

IC

A L

C E

N T

S

W A

R C

H E

R R

O A

D

G A

IN

E

SV

IL

L E

, F L

O R

U

IL

D

E R

IO

R

T

E R

C A

T

M

PO

N E

L

N C

E N

T R

A T

Y

W E

IG

H

T ld in g

In te rio r D

9-an d D

0-

W oo d

D ld in g

In te rio r

D

9-an d

D

0-

Pl as te r W ld in g

In te rio r D

9-an d D

0-

D ry w al l W ld in g

In te rio r A

4-an d A

5-

W oo d

D oo r F ra y

0.

ld in g

In te rio r

A

4-an d

A

5-

Pl as te r W ld in g

In te rio r C

2-

M et al

D oo r F ra m e ld in g

In te rio r C

2-

W oo d

D oo r G ra y

0.

ld in g

In te rio r

C

2-

Pl as te r W

-6

B ui ld in g

In te

3- 1, E

6- 1, E B

-1

, E B

-1

E

B

-1 , E

B

-1 , F

4-

1, F

-1 , F

B

-1 , G

3-

1, a nd G

4-

M et al

D oo r Fr am e

L ig ht B lu e

0.

ld in g

In te rio r E1 w al l W ld in g

In te rio r E1 w al l W ld in g

In te rio r E1 al

D oo r F ra m e

C ld in g

In te rio r

E1 w al l W al ls a nd C ei lin g C ld in g

In te rio r

EB

-1

, E B4

6- 1, E B

-1

, a nd

E B d

D t B lu e

0.

ld in g

In te rio r

EB

w al l W

-7

B ui ld in g

In te

-1 a nd

E B w al l W ld in g

In te rio r

F1 w al l W ld in g

In te rio r F1

-1

, F B0

3- 1, F B0

4- 1, G

3- 1, 4-

C er am ic T ile W y

0.

ld in g

In te rio r

FB

-1 a nd

F B0

4-

D ry w al l W ld in g

In te rio r

G

3-an d

G

4-

Ex te rio r M et al

D oo r F ra ed ld in g

In te rio r

G

3-an d

G

4-

D ry w al l W

-8

B ui ld in g

In te w al l W

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 19

B L

E

.2 -1

SU

M M

A R

Y O

F A

N A

L Y

T

IC

A L

R E

SU

L

T S

R E

N O

V A

T E

C O

M M

O N

A R

E A

R E

ST

R

O O

M S

PR

O

JE

C

T

-2

0-

M

A L

C O

M R

A N

D A

L L

V A

M E

D

IC

A L

C E

N T

S

W A

R C

H E

R R

O A

D

G A

IN

E

SV

IL

L E

, F L

O R

U

IL

D

E R

IO

R

T

E R

C A

T

M

PO

N E

L

N C

E N

T R

A T

Y

W E

IG

H

T ld in g

In rio r

6-

, 1

-1

2, -1

2, -1

2, 8-

, a nd

-1

M et al

D oo r F ra e

0.

ld in g

In rio r

6-

, 1

-1

2, -1

2, -1

2, 8-

, a nd

-1

D ry w al l W ld in g

In te rio r C

1-an d C2 te r W ld in g

In te rio r C w al l W ld in g

In te rio r

C

3-

Pl as te r W en

1 B

L D re su lt in di ca te s l ea d-co nt ai ni ng p ai nt

2 T he r eq ui re m en ts o f th e O

SH

A

L ea d in

C on st ru ct io n St an da rd

9C

FR

6.

a re in vo ke d if an y am ou nt o f le ad is p re se nt in th e sa m pl e;

th er e is n o m in im um c on ce nt ra tio n.

e re su lts o f t he la bo ra to ry a na ly se s a re in cl ud ed in A pp en di x

App E - 20

4.0 CONCLUSIONS AND RECOMMENDATIONS

4.1 ASBESTOS – GENERAL

Asbestos-containing materials (ACMs) were identified in the scope of this survey. General and specific conclusions and recommendations are provided below.

The EPA, OSHA and the State of Florida have promulgated regulations dealing with asbestos.

For commercial building owners, the EPA NESHAP (40 CFR 61) regulations require removal of RACM, prior to conducting activities which might disturb the material. They also deal with notification, handling and disposal of asbestos.

The EPA recommends that an Operations and Maintenance (O&M) Program be developed for any facilities with ACM, and this Program should address all ACM (known and/or assumed) present. The O&M Program establishes notification and training requirements along with special procedures for working around the ACM. The O&M Program would remain in effect until all asbestos is removed.

Category I and Category II non-friable materials, as defined by the EPA, may remain within a facility during demolition with no potential cessation of work, provided they remain non-friable and the appropriate engineering controls (i.e., wet methods) are utilized, with the resulting waste disposed of as asbestos-containing waste. However, there is no guarantee that these materials will remain non-friable. If the materials become friable, then they are classified as RACM.

RACM, as defined by the EPA, must be removed prior to renovation or demolition activities that may disturb the materials.

The OSHA regulations deal with employee exposure to airborne asbestos fibers. The regulations restrict employee exposure, and require special monitoring, training and handling procedures when dealing with asbestos. Additionally, OSHA has regulations that may supersede the EPA regulations. In order to protect the worker, OSHA has established a permissible exposure limit (PEL), which limits employee exposure to airborne fiber concentrations. OSHA requires objective evidence that the PEL will not be exceeded, as justification that personal air monitoring and engineering controls will not be required. OSHA has also established rules requiring the containerization and labeling of asbestos waste.

The State regulations require that anyone involved in asbestos consulting activities be a licensed asbestos consultant and that anyone involved in asbestos abatement, with the exception of roofing materials, be a licensed asbestos abatement contractor.

4.1.1 ASBESTOS – SPECIFIC

FT-04: Black Mastic Associated with 12" x 12" Beige Floor Tile M-28: White Caulk

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 21

MAS-01: Cream Duct Mastic MAS-03: Tan Mastic MAS-10: Cream Duct Mastic MAS-15: White Mastic MAS-19: White Duct Mastic MAS-20: White Duct Mastic TSI-02: Black Elbow Mastic TSI-04: Black Elbow Mastic TSI-05: White Mastic over Elbow Mud

These materials are defined by the EPA as Category I non-friable materials. These materials do not appear to present a significant issue, as observed, at the time of the survey. We recommend that the identified ACM be maintained as part of an O&M Program and periodically monitored for any changes in condition. Additionally, we recommend that a licensed asbestos abatement contractor properly remove and dispose of the ACM prior to conducting renovation activities that might disturb the ACM.

Inaccessible Areas

Access to plenum spaces was limited at the time of the survey. Should planned renovation and/or demolition activities involve the disturbance of previously unidentified materials in these areas, we recommend that these materials be sampled and analyzed for asbestos content, and if determined to be ACM, be properly removed and disposed of by a licensed asbestos abatement contractor prior to conducting such activities.

Drywall System

The drywall system sample constituents were reported as “no asbestos detected” for the drywall and greater than one percent (> one percent) asbestos for the joint compound.

Composite sample analyses (combining the drywall and joint compound constituents) were reported as less than or equal to one percent asbestos. These drywall system samples are classified by the EPA as non-asbestos containing materials, when the samples are represented as a system composite with asbestos content of less than or equal to one percent asbestos. However, OSHA regulations offer differing opinions regarding the status of drywall joint compound when subjected to disturbance. Therefore, GLE recommends that the material be considered for removal by a licensed asbestos abatement contractor prior to disturbance (i.e. removal, sanding, cutting, etc.) as part of a renovation project. However, if maintained wet, the material may remain in-place during renovation and/or demolition activities provided sufficient documentation is obtained indicating personnel performing work are not exposed to asbestos fiber levels above OSHA's PEL of 0.1 fibers per cubic centimeter (f/cc). This documentation may be obtained by performing air monitoring as required by OSHA.

< One Percent Asbestos Building Material M-26: Gray Ceramic Tile Grout

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 22

This building material is classified by the EPA as a non-asbestos containing material based on the analytical results. However, OSHA regulations still apply. Therefore, GLE recommends that the material be considered for removal by a licensed asbestos abatement contractor, prior to disturbance (i.e. removal, sanding, cutting, etc.), as part of a renovation or demolition project. However, if maintained wet, the material may remain in-place during renovation and/or demolition activities, provided sufficient documentation is obtained indicating personnel performing work are not exposed to asbestos fiber levels above OSHA's PEL of 0.1 fibers per cubic centimeter (f/cc). This documentation may be obtained by performing air monitoring as required by OSHA.

4.2 LEAD-CONTAINING PAINT

Lead-containing paint (LCP) was identified in eleven (11) of the seventy-two (72) samples.

Under the present OSHA lead construction standard, all identified lead-containing paint affected by construction activities falls under the requirements of 29 CFR 1926. There are no current government guidelines defining a lead paint concentration that creates a hazardous atmosphere when disturbed. Based on current OSHA guidelines, for those employees who will be disturbing lead-containing paint, their employer must make an initial determination by monitoring employee exposure if any employee is exposed to lead at or above the established Permissible Exposure Limit (PEL) of 30 µg/m3 (8-hour TWA).

The employer must implement OSHA prescribed protective measures until they can demonstrate that the employee exposure is not in excess of the PEL. Due to the planned demolition or renovations for these facilities, GLE’s recommendations are as follows:

For all identified lead painted materials where abrasive blasting, welding, cutting and/or torch burning are planned, removal of lead paint is to be completed by a properly trained lead removal contractor.

For all identified lead painted materials where manual demolition (e.g. drywall), manual scraping, manual sanding and heat gun applications are planned: provide workers with interim protection as outlined in the OSHA Lead in Construction Standard until the employee exposure monitoring indicates that that all tasks being performed are not exposing employees above the

PEL.

The interim employee protection measures include but are not limited to the following:

appropriate respiratory protection; appropriate personal protective clothing and equipment;

change areas; hand washing facilities; biological monitoring; and training.

All waste generated during the lead paint removal and during subsequent manual demolition or renovation activities should be characterized by Toxicity Characteristic Leaching Procedure testing for lead for waste disposal purposes.

App E - 23

5.0 LIMITATIONS AND CONDITIONS

As a result of previous renovations, there may be hidden materials, such as floor tile, sheet vinyl flooring, insulation, etc. These materials may be found in various areas hidden under existing flooring materials or in wall cavities. Any materials or coatings found during construction activities, either not addressed in this survey report, or similar to the ACM or LCP identified in this survey report should be assumed to be ACM or LCP until sampling and analysis documents otherwise.

Because of the hidden nature of many building components (i.e. within mechanical chases), it may be impossible to determine if all of the suspect building materials have been located and subsequently tested. Destructive testing in some instances is not a viable option. We cannot, therefore, guarantee that all potential ACM or LCP has been located. For the same reasons, estimates of quantities and/or conditions are subject to readily apparent situations, and our findings reflect this condition. We do warrant, however, that the investigations and methodology reflect our best efforts based upon the prevailing standard of care in the environmental industry.

The information contained in this report was prepared based upon specific parameters and regulations in force at the time of this report. The information herein is only for the specific use of the Client and GLE. GLE accepts no responsibility for the use, interpretation, or reliance by other parties on the information contained herein, unless prior written authorization has been obtained from GLE.

App E - 24

APPENDIX A

Analytical Results and Chains of Custody

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 25

SUMMARY OF BULK SAMPLE ANALYSIS

TMM; MRMC Restrooms 22950-00685

Sample Sample Type Fiber Type

CT-01A 2' X 4' White Fissured

Ceiling Tile 100% Mineral Wool

CT-01B 2' X 4' White Fissured

Ceiling Tile 100% Mineral Wool

CT-01C-QC 2' X 4' White Fissured

Ceiling Tile 100% Mineral Wool

CT-02A 2' X 2' White Recessed

Fissured Ceiling Tile 100% Mineral Wool

CT-02B 2' X 2' White Recessed

Fissured Ceiling Tile 100% Mineral Wool

CT-02C 2' X 2' White Recessed

Fissured Ceiling Tile 100% Mineral Wool

CT-03A 2' X 2' White Fissured

Ceiling Tile 100% Mineral Wool

CT-03B 2' X 2' White Fissured

Ceiling Tile 100% Mineral Wool

CT-03C 2' X 2' White Fissured

Ceiling Tile 100% Mineral Wool

CT-05A 2' X 4' White Pinhole

Ceiling Tile 100% Mineral Wool

CT-05B 2' X 4' White Pinhole

Ceiling Tile 100% Mineral Wool

CT-05C 2' X 4' White Pinhole

Ceiling Tile 100% Mineral Wool

Darryl Neldner

* Polarized Light Microscopy coupled with dispersion is the technique used for identification in accordance with EPA 600/M4-82-020, EPA 600/R-93/116, and NIOSH Method 9002.

** The percentage of each component is visually estimated. The result of this analysis relate only to the material tested.

The report shall not be used to claim product endorsement by NVLAP or any agency of the U.S. Government.

(>1% greater than one percent, <1% less than one percent) QC - Sample reanalyzed for QA/QC.

Analysis performed by GLE Associates, Inc. NVLAP Code 102003-0, CO AL-17485, TX 30-0337

*** This report shall not be reproduced except in full, without the written approval of the laboratory. GLE Report # 27055

Analyst / Approved

Signatory:

Feedback regarding laboratory performance should be addressed to lab@gleassociates.com.

Report Date: 3/29/2022

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 26

22950-00685

Sample Sample Type Fiber Type

CT-07A-QC 2' X 2' White Fissured &

Pinholes Ceiling Tile 100% Mineral Wool

CT-07B 2' X 2' White Fissured &

Pinholes Ceiling Tile 100% Mineral Wool

CT-07C 2' X 2' White Fissured &

Pinholes Ceiling Tile 100% Mineral Wool

CT-08A 2' X 4' White Fissured &

Pinholes Ceiling Tile 100% Mineral Wool

CT-08B 2' X 4' White Fissured &

Pinholes Ceiling Tile 100% Mineral Wool

CT-08C 2' X 4' White Fissured &

Pinholes Ceiling Tile 100% Mineral Wool

CT-20A 2' X 2' White Pinhole

Ceiling Tile 100% Mineral Wool

CT-20B 2' X 2' White Pinhole

Ceiling Tile 100% Mineral Wool

CT-20C 2' X 2' White Pinhole

Ceiling Tile 100% Mineral Wool

CT-24A 2' X 2' White Recessed

Fissured Ceiling Tile 100% Mineral Wool

CT-24B-QC 2' X 2' White Recessed

Fissured Ceiling Tile 100% Mineral Wool

CT-24C 2' X 2' White Recessed

Fissured Ceiling Tile 100% Mineral Wool

Darryl Neldner

* Polarized Light Microscopy coupled with dispersion is the technique used for identification in accordance with EPA 600/M4-82-020, EPA 600/R-93/116, and NIOSH Method 9002.

** The percentage of each component is visually estimated. The result of this analysis relate only to the material tested.

The report shall not be used to claim product endorsement by NVLAP or any agency of the U.S. Government.

(>1% greater than one percent, <1% less than one percent) QC - Sample reanalyzed for QA/QC.

Analysis performed by GLE Associates, Inc. NVLAP Code 102003-0, CO AL-17485, TX 30-0337

*** This report shall not be reproduced except in full, without the written approval of the laboratory. GLE Report # 27055

Analyst / Approved

Signatory:

Feedback regarding laboratory performance should be addressed to lab@gleassociates.com.

Report Date: 3/29/2022

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 27

22950-00685

Sample Sample Type Fiber Type

CT-27A 2' X 2' White Fissured

Ceiling Tile 100% Mineral Wool

CT-27B 2' X 2' White Fissured

Ceiling Tile 100% Mineral Wool

CT-27C 2' X 2' White Fissured

Ceiling Tile 100% Mineral Wool

CT-31A 2' X 2' White Fissured

Ceiling Tile 100% Mineral Wool

CT-31B 2' X 2' White Fissured

Ceiling Tile 100% Mineral Wool

CT-31C 2' X 2' White Fissured

Ceiling Tile 100% Mineral Wool

DW-01A Drywall 100% Gypsum, Quartz, Calcite, Clay

DW-01B Drywall 100% Gypsum, Quartz, Calcite, Clay

DW-01C-QC Drywall 100% Gypsum, Quartz, Calcite, Clay

DW-02A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-02B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-02C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-03A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

Darryl Neldner

* Polarized Light Microscopy coupled with dispersion is the technique used for identification in accordance with EPA 600/M4-82-020, EPA 600/R-93/116, and NIOSH Method 9002.

** The percentage of each component is visually estimated. The result of this analysis relate only to the material tested.

The report shall not be used to claim product endorsement by NVLAP or any agency of the U.S. Government.

(>1% greater than one percent, <1% less than one percent) QC - Sample reanalyzed for QA/QC.

Analysis performed by GLE Associates, Inc. NVLAP Code 102003-0, CO AL-17485, TX 30-0337

*** This report shall not be reproduced except in full, without the written approval of the laboratory. GLE Report # 27055

Analyst / Approved

Signatory:

Feedback regarding laboratory performance should be addressed to lab@gleassociates.com.

Report Date: 3/29/2022

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 28

22950-00685

Sample Sample Type Fiber Type

DW-03B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-03C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-04A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-04B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-04C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-05A-QC

Overall asbestos concentration is <1% by composite sample analysis and is not considered an asbestos containing material by EPA definition.

Drywall

Joint Compound 5% Chrysotile Asbestos

95% Quartz, Calcite, Clay, Mica

Composite Total <1% Chrysotile Asbestos

100% Gypsum, Quartz, Calcite, Clay

DW-05B

Overall asbestos concentration is <1% by composite sample analysis and is not considered an asbestos containing material by EPA definition.

Drywall 100% Gypsum, Quartz, Calcite, Clay

Joint Compound 5% Chrysotile Asbestos

95% Quartz, Calcite, Clay, Mica

Composite Total <1% Chrysotile Asbestos

100% Gypsum, Quartz, Calcite, Clay

Darryl Neldner

* Polarized Light Microscopy coupled with dispersion is the technique used for identification in accordance with EPA 600/M4-82-020, EPA 600/R-93/116, and NIOSH Method 9002.

** The percentage of each component is visually estimated. The result of this analysis relate only to the material tested.

The report shall not be used to claim product endorsement by NVLAP or any agency of the U.S. Government.

(>1% greater than one percent, <1% less than one percent) QC - Sample reanalyzed for QA/QC.

Analysis performed by GLE Associates, Inc. NVLAP Code 102003-0, CO AL-17485, TX 30-0337

*** This report shall not be reproduced except in full, without the written approval of the laboratory. GLE Report # 27055

Analyst / Approved

Signatory:

Feedback regarding laboratory performance should be addressed to lab@gleassociates.com.

Report Date: 3/29/2022

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 29

22950-00685

Sample Sample Type Fiber Type

DW-05C

Overall asbestos concentration is <1% by composite sample analysis and is not considered an asbestos containing material by EPA definition.

Drywall 100% Gypsum, Quartz, Calcite, Clay

Joint Compound 5% Chrysotile Asbestos

95% Quartz, Calcite, Clay, Mica

Composite Total <1% Chrysotile Asbestos

100% Gypsum, Quartz, Calcite, Clay

DW-06A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-06B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-06C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-07A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-07B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-07C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-08A Drywall 100% Gypsum, Quartz, Calcite, Clay

DW-08B-QC Drywall 100% Gypsum, Quartz, Calcite, Clay

DW-08C Drywall 100% Gypsum, Quartz, Calcite, Clay

DW-09A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

Darryl Neldner

* Polarized Light Microscopy coupled with dispersion is the technique used for identification in accordance with EPA 600/M4-82-020, EPA 600/R-93/116, and NIOSH Method 9002.

** The percentage of each component is visually estimated. The result of this analysis relate only to the material tested.

The report shall not be used to claim product endorsement by NVLAP or any agency of the U.S. Government.

(>1% greater than one percent, <1% less than one percent) QC - Sample reanalyzed for QA/QC.

Analysis performed by GLE Associates, Inc. NVLAP Code 102003-0, CO AL-17485, TX 30-0337

*** This report shall not be reproduced except in full, without the written approval of the laboratory. GLE Report # 27055

Analyst / Approved

Signatory:

Feedback regarding laboratory performance should be addressed to lab@gleassociates.com.

Report Date: 3/29/2022

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 30

22950-00685

Sample Sample Type Fiber Type

DW-09B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-09C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-10A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-10B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-10C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-11A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-11B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-11C-QC Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-12A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-12B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-12C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-13A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

Darryl Neldner

* Polarized Light Microscopy coupled with dispersion is the technique used for identification in accordance with EPA 600/M4-82-020, EPA 600/R-93/116, and NIOSH Method 9002.

** The percentage of each component is visually estimated. The result of this analysis relate only to the material tested.

The report shall not be used to claim product endorsement by NVLAP or any agency of the U.S. Government.

(>1% greater than one percent, <1% less than one percent) QC - Sample reanalyzed for QA/QC.

Analysis performed by GLE Associates, Inc. NVLAP Code 102003-0, CO AL-17485, TX 30-0337

*** This report shall not be reproduced except in full, without the written approval of the laboratory. GLE Report # 27055

Analyst / Approved

Signatory:

Feedback regarding laboratory performance should be addressed to lab@gleassociates.com.

Report Date: 3/29/2022

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 31

22950-00685

Sample Sample Type Fiber Type

DW-13B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-13C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-14A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-14B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-14C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-15A-QC Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-15B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-15C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-16A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-16B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-16C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-17A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

Darryl Neldner

* Polarized Light Microscopy coupled with dispersion is the technique used for identification in accordance with EPA 600/M4-82-020, EPA 600/R-93/116, and NIOSH Method 9002.

** The percentage of each component is visually estimated. The result of this analysis relate only to the material tested.

The report shall not be used to claim product endorsement by NVLAP or any agency of the U.S. Government.

(>1% greater than one percent, <1% less than one percent) QC - Sample reanalyzed for QA/QC.

Analysis performed by GLE Associates, Inc. NVLAP Code 102003-0, CO AL-17485, TX 30-0337

*** This report shall not be reproduced except in full, without the written approval of the laboratory. GLE Report # 27055

Analyst / Approved

Signatory:

Feedback regarding laboratory performance should be addressed to lab@gleassociates.com.

Report Date: 3/29/2022

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 32

22950-00685

Sample Sample Type Fiber Type

DW-17B Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-17C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-18A Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-18B-QC Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

DW-18C Drywall & Joint

Compound 100% Gypsum, Quartz, Calcite, Clay

FT-02A 12" X 12" White Floor

Tile & Yellow Glue 100% Polymer, Quartz, Calcite, Clay, Mica

FT-02B 12" X 12" White Floor

Tile & Yellow Glue 100% Polymer, Quartz, Calcite, Clay, Mica

FT-02C 12" X 12" White Floor

Tile & Yellow Glue 100% Polymer, Quartz, Calcite, Clay, Mica

FT-03A 12" X 12" Blue Floor Tile

& Yellow Glue 100% Polymer, Quartz, Calcite, Clay, Mica

FT-03B 12" X 12" Blue Floor Tile

& Yellow Glue 100% Polymer, Quartz, Calcite, Clay, Mica

FT-03C 12" X 12" Blue Floor Tile

& Yellow Glue 100% Polymer, Quartz, Calcite, Clay, Mica

Darryl Neldner

* Polarized Light Microscopy coupled with dispersion is the technique used for identification in accordance with EPA 600/M4-82-020, EPA 600/R-93/116, and NIOSH Method 9002.

** The percentage of each component is visually estimated. The result of this analysis relate only to the material tested.

The report shall not be used to claim product endorsement by NVLAP or any agency of the U.S. Government.

(>1% greater than one percent, <1% less than one percent) QC - Sample reanalyzed for QA/QC.

Analysis performed by GLE Associates, Inc. NVLAP Code 102003-0, CO AL-17485, TX 30-0337

*** This report shall not be reproduced except in full, without the written approval of the laboratory. GLE Report # 27055

Analyst / Approved

Signatory:

Feedback regarding laboratory performance should be addressed to lab@gleassociates.com.

Report Date: 3/29/2022

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 33

22950-00685

Sample Sample Type Fiber Type

FT-04A 12" X 12" Beige Floor Tile 100% Polymer, Quartz, Calcite, Clay, Mica

Black Mastic 5% Chrysotile Asbestos

95% Bitumen

FT-04B 12" X 12" Beige Floor Tile 100% Polymer, Quartz, Calcite, Clay, Mica

Black Mastic Positive Stop/Sample not analyzed

FT-04C-QC 12" X 12" Beige Floor Tile 100% Polymer, Quartz, Calcite, Clay, Mica

Black Mastic Positive Stop/Sample not analyzed

M-01A White Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-01B White Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-01C White Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-02A Gray Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-02B Gray Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-02C Gray Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-03A Speckled Epoxy Flooring 100% Quartz, Calcite, Clay, Mica

M-03B Speckled Epoxy Flooring 100% Quartz, Calcite, Clay, Mica

M-03C Speckled Epoxy Flooring 100% Quartz, Calcite, Clay, Mica

M-04A-QC Tan Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

Darryl Neldner

* Polarized Light Microscopy coupled with dispersion is the technique used for identification in accordance with EPA 600/M4-82-020, EPA 600/R-93/116, and NIOSH Method 9002.

** The percentage of each component is visually estimated. The result of this analysis relate only to the material tested.

The report shall not be used to claim product endorsement by NVLAP or any agency of the U.S. Government.

(>1% greater than one percent, <1% less than one percent) QC - Sample reanalyzed for QA/QC.

Analysis performed by GLE Associates, Inc. NVLAP Code 102003-0, CO AL-17485, TX 30-0337

*** This report shall not be reproduced except in full, without the written approval of the laboratory. GLE Report # 27055

Analyst / Approved

Signatory:

Feedback regarding laboratory performance should be addressed to lab@gleassociates.com.

Report Date: 3/29/2022

Renovate Common Area Restrooms, Project No. 573-20-604, TMM-2110

App E - 34

22950-00685

Sample Sample Type Fiber Type

M-04B Tan Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-04C Tan Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-05A White Caulk 100% Polymer, Quartz, Calcite, Clay, Mica

M-05B White Caulk 100% Polymer, Quartz, Calcite, Clay, Mica

M-05C White Caulk 100% Polymer, Quartz, Calcite, Clay, Mica

M-06A Gray Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-06B Gray Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-06C Gray Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-08A Tan Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-08B-QC Tan Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-08C Tan Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-09A Tan Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-09B Tan Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-09C Tan Ceramic Tile Grout 100% Quartz, Calcite, Clay, Mica

M-10A White Caulk 100% Polymer, Quartz, Calcite, Clay, Mica

M-10B White Caulk 100% Polymer, Quartz, Calcite, Clay, Mica

Darryl Neldner

* Polarized Light Microscopy coupled with dispersion is the technique used for identification in accordance with EPA 600/M4-82-020, EPA 600/R-93/116, and NIOSH Method 9002.

** The percentage of each component is visually estimated. The result of this analysis relate only to the material tested.

The report shall not be used to claim product endorsement by NVLAP or any agency of the U.S. Government.

(>1% greater than one percent, <1% less than one percent) QC - Sample reanalyzed for QA/QC.

Analysis performed by GLE Associates, Inc. NVLAP Code 102003-0, CO AL-17485, TX 30-0337

*** This report shall not be reproduced except in full, without the written approval of the laboratory. GLE Report # 27055

Analyst / Approved

Signatory:

Feedback regarding laboratory…